About Evommune
Evommune is a company based in Sacramento (United States) founded in 2020 by Luis Pena.. Evommune has raised $275.5 million across 5 funding rounds from investors including Beiersdorf, EQT and Marshall Wace. Evommune offers products and services including EVO756 and EVO301. Evommune operates in a competitive market with competitors including Aclaris Therapeutics, Incyte, Escient Pharmaceuticals, LEO Pharma and Nimbus Therapeutics, among others.
- Headquarter Sacramento, United States
- Founders Luis Pena
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Evommune, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$275.5 M (USD)
in 5 rounds
-
Latest Funding Round
$115 M (USD), Series C
Oct 30, 2024
-
Investors
Beiersdorf
& 18 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Evommune
Evommune is a publicly listed company on the NYSE with ticker symbol EVMN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Evommune
Evommune offers a comprehensive portfolio of products and services, including EVO756 and EVO301. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
MRGPRX2 antagonist for treating chronic spontaneous urticaria.
IL-18 targeted therapy for atopic dermatitis management.
Unlock access to complete
Funding Insights of Evommune
Evommune has successfully raised a total of $275.5M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $115 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series C — $115.0M
-
First Round
First Round
(22 Oct 2020)
- Investors Count 19
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2024 | Amount | Series C - Evommune | Valuation | RA Capital Management , Sectoral | |
| Jun, 2023 | Amount | Series B - Evommune | Valuation | Verition Fund Management |
|
| Mar, 2023 | Amount | Series B - Evommune | Valuation | Arix Bioscience , EQT |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Evommune
Evommune has secured backing from 19 investors, including institutional and venture fund investors. Prominent investors backing the company include Beiersdorf, EQT and Marshall Wace. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sectoral Asset Management is focused on global healthcare investment.
|
Founded Year | Domain | Location | |
|
Life Sciences focused VC firm investing in the US
|
Founded Year | Domain | Location | |
|
Multistage investments are directed toward technology, healthcare, and climate sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Evommune
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Evommune
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Evommune Comparisons
Competitors of Evommune
Evommune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Incyte, Escient Pharmaceuticals, LEO Pharma and Nimbus Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating dermatology diseases
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
AI-powered drug discovery platform for various diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Evommune
Frequently Asked Questions about Evommune
When was Evommune founded?
Evommune was founded in 2020.
Where is Evommune located?
Evommune is headquartered in Sacramento, United States. It is registered at Sacramento, California, United States.
Who is the current CEO of Evommune?
Luis Pena is the current CEO of Evommune. They have also founded this company.
Is Evommune a funded company?
Evommune is a funded company, having raised a total of $275.5M across 5 funding rounds to date. The company's 1st funding round was a Series B of $57.5M, raised on Oct 22, 2020.
What does Evommune do?
Evommune was founded in 2020 and is based in Sacramento, United States. Focus is placed on the biotechnology sector, where therapeutic candidates for chronic inflammatory disorders are developed. The pipeline includes options targeting IL-37 for rosacea and atopic dermatitis, RORγt for psoriasis, MRGPRX2 for pruritus, and PKCθ for atopic dermatitis. A tissue-based screening platform is utilized to support drug development for these conditions.
Who are the top competitors of Evommune?
Evommune's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and LEO Pharma.
What products or services does Evommune offer?
Evommune offers EVO756 and EVO301.
Is Evommune publicly traded?
Yes, Evommune is publicly traded on NYSE under the ticker symbol EVMN.
Who are Evommune's investors?
Evommune has 19 investors. Key investors include Beiersdorf, EQT, Marshall Wace, RTW Investments, and RA Capital.
What is Evommune's ticker symbol?
The ticker symbol of Evommune is EVMN on NYSE.